<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554240</url>
  </required_header>
  <id_info>
    <org_study_id>DA5202_KOA_II</org_study_id>
    <nct_id>NCT02554240</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>Active-controlled, Dose-Response, Randomized, Double-blind, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II clinical study is to evaluate the efficacy and safety of DA-5202 in patients
      with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects are randomly assigned to receive DA-5202 high dose(20mg) or DA-5202 low
      dose(10mg) or Na Hyaluronate once a week intra-articular injection for 3 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of 100mm-VAS about weight bearing pain in study knee at week 3</measure>
    <time_frame>week 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of 100mm-VAS about Weight bearing pain in study knee at week 1,2,7,12</measure>
    <time_frame>week 1,2,7,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of 100mm-VAS about Resting pain in study knee at week 1,2,3,7,12</measure>
    <time_frame>week 1,2,3,7,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>knee joint range of motion change (Observation by investigator)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>knee joint effusion change (Observation by investigator)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall assessment of subject and investigator (5-Likert scale)</measure>
    <time_frame>week 1,2,3,7,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of 100mm-VAS about Motion pain in study knee at week 1,2,3,7,12</measure>
    <time_frame>week 1,2,3,7,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of 100mm-VAS about Night pain in study knee at week 1,2,3,7,12</measure>
    <time_frame>week 1,2,3,7,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of WOMAC Index total score at Week 1,2,3,7,12</measure>
    <time_frame>week 1,2,3,7,12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>DA-5202 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- DA-5202 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-5202 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- DA-5202 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Na Hyaluronate 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Na Hyaluronate 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5202 20mg</intervention_name>
    <description>once a week, intra-articular injection, for 3 weeks</description>
    <arm_group_label>DA-5202 High dose</arm_group_label>
    <other_name>DA-5202 high dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5202 10mg</intervention_name>
    <description>once a week, intra-articular injection, for 3 weeks</description>
    <arm_group_label>DA-5202 Low dose</arm_group_label>
    <other_name>DA-5202 low dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Na Hyaluronate 20mg</intervention_name>
    <description>once a week, intra-articular injection, for 3 weeks</description>
    <arm_group_label>Na Hyaluronate 20mg</arm_group_label>
    <other_name>Hyruan Plus®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female patients between 20 and 80 y old

          -  primary knee osteoarthritis confirmed clinically and radiologically according to
             American College of Rheumatology criteria and have following 3 items

               1. knee joint pain

               2. have any of the following

                    1. males and females more than 50 y

                    2. morning stiffness within 30 minutes

                    3. crepitus

               3. presence of spur on radiological evidence

          -  Kellgren-Lawrence Grade Ⅰ to Ⅲ confirmed radiologically

          -  knee pain under weight-bearing greater than 40/100mm-VAS(Visual Analogue Scale) at
             randomization visit

          -  patients willing and able to provide signed informed consent after the nature of the
             study has been explained

        Exclusion Criteria:

          -  BMI(Body Mass Index) &gt; 32

          -  complete obliteration of femoropatellar joint space on X-ray

          -  Kellgren-Lawrence Grade IV

          -  knee surgery within a year

          -  history of fracture, rheumatoid arthritis or other inflammatory arthritis in knee
             articular cavity

          -  intra-articular corticosteroid injection within 3 months or hyaluronate injection
             within 6 months

          -  skin diseases or infection overlying the joint

          -  history of severe drug allergy or hypersensitivity to drugs(piroxicam, hyaluronic
             acid)

          -  history of allergy, asthma, rhinitis, angioedema, rash to aspirin or other NSAIDs
             (including COX-2 inhibitor)

          -  treatment with anticoagulants such as heparin or coumarins (warfarin etc.)

          -  History of GI diseases such as peptic ulcer, bleeding, perforation, ulcerative
             colitis, Crohn's disease within 1 year

          -  severe hypertension

          -  patients with psychiatric disorder, alcoholism, drug addiction

          -  presence of severe concomitant diseases or malignancy within 5 years

          -  have participated in another clinical trial 4 weeks prior to the study

          -  women of child-bearing potential who are not using *adequate means of contraception
             (*adequate means of contraception: condom, oral contraception, barrier methods using
             spermicide, intrauterine devices etc.)

          -  any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung chul Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung chul Lee, MD, PhD</last_name>
    <phone>+82-2-2072-3212</phone>
    <email>leemc@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2015</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

